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CHAPTER I 
 
INTRODUCTION 
 
 Current treatments for cancer rely on systemic administration of 
chemotherapeutic drugs with the goal of maximizing damage to tumor cells despite 
exposure and toxicity to healthy tissues.  This approach is beneficial for damaging 
tumor tissue but due to the many side effects of these cytotoxic drugs, healthy tissues 
can be damaged and organ function can be compromised. Targeted delivery of drugs to 
tumors attempts to improve the bioavailability of drugs at the tumor site while reducing 
systemic toxicity to healthy organs and tissues. The efficacy of traditional cytotoxic 
cancer therapies comes with the price of significant toxicity to normal cells, which can 
limit the success of therapy. Greater understanding of the molecular differences 
between cancer cells and normal cells has led to the development of therapies that 
target cancer cells, including antibodies targeted at tumor associated antigens. The 
targeted nature of such therapies offers the promise of greater efficacy and less toxicity, 
and potentially greater treatment success.   
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Vascular Targeting 
 
 Tumor angiogenesis is recognized as essential for the growth and progression 
of all tumor types, therefore, targeting the delivery of cytotoxic and radiosensitizing drugs 
to tumor blood vessels is an important approach in the treatment of cancer. The lumen of 
tumor microvasculature is composed of a monolayer of endothelial cells that controls 
vascular tone, blood flow and extravasation of components from the bloodstream 1. This 
microvascular tissue plays an essential role in the process of inflammation and is 
affected by radiation therapy used in many cancer treatments. Radiation therapy is 
typically used to treat tumors locally, but it can also be used to “guide” drugs to specific 
sites by creating localized areas of inflammation and inducing the expression of 
radiation-specific receptors in tumors, including P-selectin 2,3. Studies have shown that 
ionizing radiation causes oxidative injury in endothelial cells, which in turn respond by 
activating the process of inflammation and platelet aggregation through cell adhesion 
molecules (CAMs) 4,5,6. These molecules include ICAM-1, VCAM, integrins, and selectins 
among others. Once vascular endothelium is exposed to ionizing radiation, proteins 
contained within storage reservoirs in endothelial cells are transported to the cell 
membrane, where they can serve as receptors for radiation-targeted drug delivery 2,3.  
 Tumor microvascular endothelium that has been exposed to radiation 
expresses many receptors that can be identified and targeted, including molecules in the 
selectin family 7. These molecules are expressed on leukocytes (L-selectin), endothelial 
cells (E-selectin, P-selectin) and platelets (P-selectin).  These cell adhesion molecules 
are known for mediating leukocyte rolling on endothelial cells and platelet-leukocyte 
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aggregation 9,10,11. Studies have shown that elevated levels of selectins are present in 
the serum of subjects experiencing an inflammatory state 13. P-selectin, in particular, is 
an important disease marker as it plays an essential role in many inflammatory 
processes including cancer, coronary artery disease, stroke, and diabetes 10,13. It is also 
a valuable target for drug delivery because it is radiation-inducible, and its cellular 
expression is rapid and reversible 7,14. Due to its increased expression on endothelial 
cells, its potential as a vascular target for tumor imaging and therapy has been proposed 
in this study.  
 
Radiation Induced P-selectin 
 Radiation therapy is needed to treat approximately 60% of patients with  
cancer 7. Ionizing radiation induces the expression of cell adhesion molecules and other 
proteins in tumor microvasculature 7. Targeting radiation-induced neoantigens on tumor 
microvasculature is a valuable approach for site-specific delivery of cytotoxic drugs and 
therapeutic radionuclides. We hypothesized that radiation-induced neoantigens such as 
P-selectin can be targeted with antibodies for tumor imaging and targeted drug delivery 
to cancer.   
 P-selectin (also designated as CD62P) is a 140 kD integral glycoprotein 
originally found on the surface of activated platelets (giving rise to the designation P-
selectin) and later on endothelial cells 11,12.  It is sequestered in storage vesicles in the 
form of α-granules in platelets and Weibel-Palade bodies in endothelial cells 7,9. Upon 
exposure to ionizing radiation, P-selectin expression is stimulated and these secretory 
granules fuse with the cell membrane 7. Typically, this expression can also be induced 
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by the presence of various cytokines including histamine, thrombin, tumor necrosis factor 
alpha (TNFα) and lipopolysaccharide 7. Once P-selectin is expressed on the surface of 
endothelial cells, it is rapidly internalized by endocytosis. Its general structure consists of 
an amino-terminal lectin domain, EGF-like domain, a variable number of short 
consensus repeat units, followed by a carboxyl-terminus 11.   
 After radiation exposure, P-selectin is transiently expressed on the vascular 
endothelial cells in the lumen of the vasculature, and once inflammation has subsided it 
moves back to the cell interior 7. This transient expression enables the identification of a 
particular window of time during which targeting the tumor microvasculature can be 
particularly effective.  This approach can be used to target both therapeutic and imaging 
agents to the radiation-treated tumor.  
 
   
Basolateral 
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Lumen of 
Tumor
Tumor 
Figure 1  Schematic of endothelial cell response to ionizing radiation. 
 
In our study, we specifically examined the role of antibodies targeted to radiation-induced 
P-selectin in tumor microvasculature. This method of targeting tumors is significant 
Blood 
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because antibodies can be produced to specifically bind P-selectin, which can then be 
conjugated to drugs and other therapeutics for radiation-guided drug delivery.  
   
Therapeutic Antibodies 
 The use of therapeutic antibodies as a treatment for cancer began with the 
discovery of the structure of antibodies and the development of hybridoma technology 
15,16. These advances provided the first reliable source of monoclonal antibodies (mAbs), 
and allowed for the specific targeting of many different types of tumors. Monoclonal 
antibodies have been used in oncologic applications since the late 1990s with the 
development of rituximab (Rituxan), trastuzumab (Herceptin) and gemtuzumab 
(Mylotarg) 16. Since then, there has been an increase in the number of targeted antibody 
therapies available. Most of these therapies are based on whole, intact mAbs. While 
providing therapeutic value, these mAbs often exhibit slow clearance from the blood 
compartment to the tumor and are often too large to sufficiently penetrate the tumor 
tissue, thus limiting the efficacy of this type of therapy 17,18.  The Fc domain in these 
intact mAbs can also bind to cellular receptors and slow clearance times, creating 
systemic side effects 17. 
 One alternative to these problems has been the genetic engineering of 
antibody fragments such as single chain fragment variable (scFv) antibodies. These 
antibody fragments are comprised of immunoglobulin heavy chain and light chain 
variable regions that are connected by a short peptide linker. These antibody fragments 
retain the specific antigen-binding affinity of the parent mAb, while reducing some of the 
disadvantages associated with mAbs. Some of these advantages include their relatively 
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small size (~30 kD), which enables them to penetrate tumors more rapidly and increase 
renal clearance rates, and also their lack of an Fc domain which makes them less 
immunogenic 17-20. These advantages make scFv antibodies potentially useful for both 
tumor imaging and therapy. 
 
 
Figure 2  Schematic of intact monoclonal antibody and single chain fragment variable region. 
Modified from Brekke et. al 16. 
 
 Radionuclides have also been used with therapeutic mAbs to either increase 
therapeutic activity or exploit the targeting properties of the mAbs for cancer imaging 
21,22. Radionuclide-bearing mAbs used in the clinic include Zevalin and Bexxar 21,22. 
Although, such antibody therapies have shown significant success in cancer treatment, 
strategies to increase their efficacy are still needed. One approach has been to link 
antibodies against tumor associated antigens to highly toxic radionuclides to kill tumor 
cells 21,22. Two examples of radiolabeled antibodies include Zevalin and Bexxar, both 
anti-CD20 mAbs radiolabelled with 90Y and 131I, respectively 21,22.  
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 The selection and characterization of anti-human P-selectin ScFvs is a first 
step toward the construction of cancer imaging or new anticancer antibodies designed 
for optimal blood clearance and tumor penetration. However, very few recombinant 
antibodies are available to study the clinical function of P-selectin except for therapeutic 
attempts in the form of monoclonal antibodies and chimeric antibodies 23-27. Presently, 
there have not been any studies using P-selectin as an imaging target in cancer, partly 
due to the lack of specific desired antibodies to the protein. For these reasons, the aim of 
this study is to develop anti-human P-selectin scFvs that can be used for radiation-
guided tumor imaging. 
 
Tumor Imaging 
 The ability to non-invasively visualize P-selectin targeting in vivo would allow 
us to understand the biodistribution and pharmacokinetics of antibodies conjugated 
drugs and radionuclides targeted to tumors. In this manner, tumor growth can be 
monitored and effectiveness of therapy can be evaluated. In this study, anti-P-selectin 
scFv antibodies have been labeled with fluorescent optical probes and radionuclides for 
near-infrared optical imaging and gamma camera imaging of P-selectin expression in 
radiation treated lung tumor xenografts.  Tumor targeting efficacy and in vivo kinetics 
profiles were observed and evaluated using complementary optical and nuclear imaging 
modalities.   
 Nuclear imaging modalities such as PET, SPECT and gamma camera 
imaging typically exhibit high sensitivity in deep tissues but poor spatial and temporal 
resolution 35,36. Optical imaging modalities have the advantage of higher resolution, safer 
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use since they do not use ionizing radiation or radioactive materials, but they provide 
lower sensitivity 28-32. A major limitation of optical imaging is the high absorption and 
scattering that occurs in biological tissues and the consequently limited penetration of 
the light through the body. Near-infrared fluorescence (NIR) imaging is a particular kind 
of optical imaging that exploits the near-infrared range in the spectra to bypass the 
typical absorption and autofluorescence problems seen in optical imaging of biological     
tissues 28,29. Typically, tissues exhibit a high photon absorbance in both the visible 
wavelength range (350-650 nm) and the infrared range (above 900 nm) 28.  However, in 
the NIR range of 650-900 nm the absorbance of water and tissues in the body is at a 
minimum and thus allows photons to penetrate tissue more efficiently and minimizes 
scattering 28-32.  Functional imaging of molecularly based events such as tumor-specific 
binding can be performed using both nuclear and optical imaging modalities in order to 
provide complementary information 33,34,37. In this study, fluorescent probes in the NIR 
range were conjugated to anti-P-selectin scFvs for NIR optical imaging, and 
complementary data was gathered using 111In labeled anti-P-selectin scFvs with gamma 
camera imaging.  
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CHAPTER II 
 
METHODS 
 
Drug delivery methods generally rely on the use of targeting agents to 
deliver the conjugate to the appropriate site, and therapeutic agents to create 
the desired therapeutic effect at that site. In order to create optimal drug 
delivery vehicles, biodistribution and kinetics of the targeting agent and its 
receptor must first be studied and validated. Optical imaging and nuclear 
imaging are commonly used for these purposes and provide complementary 
information regarding targeting kinetics and biodistribution. This chapter 
focuses on the methods used for preliminary imaging studies in order to 
explore the potential of P-selectin targeting for radiation-guided drug delivery. 
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Experimental Setup 
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Antibody Selection 
  
All antibodies were screened from phage display libraries and 
developed in the Molecular Recognition Core Laboratory at Vanderbilt 
University.  The antibodies with highest affinity for P-selectin were then 
selected for in vitro and in vivo imaging studies presented here. The modified 
antibody used in the nuclear imaging studies was developed in collaboration 
with Dr. Martin Brechbiel in the radiochemistry laboratory at the National 
Institutes of Health.  
 
In Vitro Model 
 
Immunofluorescence Assay  
Primary culture human umbilical vein endothelial cells (HUVECs) were 
cultured till 80% confluency in Lab-Tek II chamber slide wells (Nunc 
International, Naperville, IL) in endothelial cell medium and incubated 37°C in 
a humidified 5% CO2 atmosphere. Cells were then incubated with human 
TNFα (500 mM) for 30 minutes. After treatment, cells were fixed with 4% 
paraformaldehyde for 10 minutes at room temperature, and washed 3 times 
with antibody buffer (4 g bovine serum albumin, 0.1 g sodium azide, 0.75 g 
glycine, and 100 µl PBS at a pH of 7). All wells were blocked with 200 µl PBS 
containing 3% bovine serum albumin for 2 hs at room temperature. Anti-P-
selectin scFv (100 µl) was added to selected wells and incubated at room 
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temperature for 1 hour in a humid chamber and then washed. The cells were 
incubated with 1 µg of biotinylated anti-E-Tag monoclonal antibody for 1 hour, 
washed 5 times with PBS-Tween solution and incubated with10 µl of a 1:200 
dilution of Alexa Fluor 488 conjugated streptavidin for 1 hour. The cells were 
washed, counterstained with DAPI, and mounted with a solution of 90% 
glycerol and 10% PBS-Tween. Cells were visualized with an Olympus BX60 
system for fluorescence microscopy. All images were obtained at an original 
magnification of 40x and imported and analyzed using Adobe Photoshop 7.0.  
 
In Vivo Model 
 
Synthesis of ScFv-Cy7 Conjugates 
 
The synthesis of Cy7-scFv conjugates was achieved through 
conjugation of monofunctional Cy7-NHS ester with the ε-amino group of the 
lysine residue of the scFv antibody (Fig. 3). The reaction was performed in a 
sodium bicarbonate buffer at a pH of 8. The dye to scFv ratio was calculated 
to be 4:1. All scFv were labeled according to Amersham Biosciences protocol 
for labeling with Cy dye NHS esters. The resulting conjugates were purified 
using a gel desalting column (G-25, Pierce). The yields of Cy7-scFv 
conjugates were typically over 80%. 
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Figure 3 Chemical structure and spectra of Cy7 fluorescent dye (Amersham)  
www.molecularprobes.com. 
 
Synthesis of 111In-DTPA-scFv10Acys Conjugates 
In order to radiolabel scFv 10A with 111In, a chelator (DTPA) was used 
for enhanced in vivo stability of the radionuclide (Fig. 4). To enable 
conjugation of scFv 10A to DTPA, a cysteine residue was engineered into the 
amino acid sequence of the scFv. The synthesis of 111In-DTPA-scFv10Acys 
conjugate was achieved through conjugation of scFv 10Acys-DTPA with 111In 
using thiol chemistry of the cysteine residue. The reaction was performed by 
adding 5 ul of 111InCl3 (3 mCi) to the scFv 10Acys-DTPA conjugate in 120 ul 
of sodium citrate (1M) buffer (pH 5) and incubating at room temperature for 1 
hr. The resulting conjugate was purified using a gel desalting column (G-25, 
Pierce). The yields of 111In-DTPA-scFv10Acys conjugate were typically over 
70% as measured by thin layer chromatography. 
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 Figure 4  Chemical structure of DTPA chelated 111In radionuclide (Amersham 
Health).  www.amersham.com 
 
Cell Culture 
Lewis lung carcinoma (LLC) cells were obtained from American Type 
Culture Collection (Mannassas VA, USA) and were cultured at 37˚C in a 
humidified atmosphere containing 5% CO2 in Dulbecco’s modified eagle 
medium supplemented with 10% fetal bovine serum and 1% penicillin 
streptomycin solution. 
Animal Models 
 
Animal studies were performed according to a protocol approved by 
Vanderbilt’s IACUC. Male athymic nude mice (nu/nu) between four to six 
weeks old (Harlan Inc., Indianapolis IN, USA) were anesthetized using a 
ketamine and xylazine solution before being injected subcutaneously in the 
right and left hind legs with 1 x 106 LLC cells suspended in 100 μL sterile 
phosphate buffered saline. Ten days after inoculation, the tumors reached an 
approximate size of 0.5-0.6 cm in diameter, and the mice were used for in 
vivo imaging studies.  
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Statistical Analysis 
 
One-way analysis of variance (ANOVA) was used for statistical 
evaluation. Means were compared by using Student’s t-test. A p-value of 
<0.05 was considered significant. 
Radiation Treatment 
Mice were irradiated with 300kV X-rays using a Pantak Therapax 3 
linear accelerator system (Pentak, East Haven, CT) using an adjustable 
collimator set to limit dosage to the tumor region only (Fig. 5).  The animals 
were anesthetized using ketamine and xylazine solution prior to irradiation to 
inhibit mobility during treatment. The left hind limb was irradiated at a dose of 
6 Gy and the right hind limb was treated with sham radiation at a dose of 0 
Gy. During irradiation procedures, 1 cm thick lead blocks were arranged 
above the rest of the body, leaving only the desired area on the hind limb 
exposed for treatment. 
 
 
Figure 5  Linear accelerator used for radiation treatments. 
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Optical Imaging 
 
In vivo NIR Fluorescence Imaging 
In vivo NIR fluorescence imaging was performed with a Xenogen IVIS 
200 small animal imaging system (Xenogen Inc., Alameda CA, USA) with a 
Cy7 filter set (excitation at 680 nm and emission at 775 nm). Nude mice 
bearing Lewis lung carcinoma tumors implanted in both hind limbs were 
treated with radiation. The tumor on the left side of each moused received a 
radiation dose of 6 Gy and the tumor on the right side received no radiation 
(sham radiation dose of 0 Gy) and served as an internal negative control. 
Three hours following radiation, mice were anesthetized using an 
intraperitoneal injection of ketamine and xylazine and prepared for tail vein 
injections of the scFv-Cy7 conjugates. The experimental group consisted of 3 
mice receiving 50 µg of scFv 10A-Cy7, and the control group of consisted of 3 
mice receiving 50 µg of scFv 4A-Cy7. 
At 1, 4 and 8 hrs post-injection, all mice were anesthetized with 
isoflurane and imaged with the Xenogen IVIS. The surface fluorescence 
intensity of each animal was measured and normalized. All fluorescence 
images were acquired with one second exposure time using an f/stop of. 
Following imaging at the final time point, mice were immediately euthanized 
by inhalation of carbon dioxide, and their tumors and major organs were 
dissected and prepared for ex vivo imaging. The total fluorescence flux 
(p/s/cm2/sr) for each organ was measured. For quantitative comparison, 
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regions of interest (ROIs) were drawn over tumors and normal tissues and the 
results were presented as mean ± standard deviation (SD) for a group of 
three animals. 
 
Nuclear Imaging 
 
In vivo Gamma Camera Imaging 
 
In vivo gamma camera imaging was performed with a large-field-of-
view Starcam General Electric gamma camera (Fig. 6).  Mice (n=3 for each 
111In-DTPA-scFv conjugate) were anesthetized with ketamine/xylazine 
solution and injected via tail vein with 500 µCi of 111In-DTPA-scFv conjugate 
containing 50 µg scFv each. Planar images were taken every 24 hours after 
injection of the 111In-DTPA conjugated scFv antibody for 10 days. Static digital 
images were collected for 10 minutes each in a 512 x 512 matrix, with typical 
counts around 500,000 at the 24-hour imaging time and fewer counts with 
each subsequent imaging session. All images were processed using ImageJ 
software provided by the NIH.   Following imaging of the final time point, mice 
were immediately euthanized by inhalation of carbon dioxide, and their 
tumors and major organs were dissected and individually labeled for well 
counts. The total counts for each organ were measured. For quantitative 
comparison, regions of interest (ROIs) were drawn over tumors and normal 
tissues in the planar images, and the results were presented as mean ± 
standard deviation (SD) for a group of three animals. 
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Figure 6 General Electric gamma camera used. 
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CHAPTER III 
 
RESULTS & DISCUSSION 
 
In Vitro Results 
 To determine whether scFv 10A bound to P-selectin in vitro, HUVECs 
were treated with TNFα to stimulate P-selectin expression on the cell 
membrane before being incubated with antibody. During immunofluorescent 
microscopy of the treated cells, it was observed that scFv 10A antibody 
bound to P-selectin protein on the cell membrane of cells treated with TNFα 
30 minutes after treatment (Fig. 7). Control scFv antibody did not show 
significant antibody binding to P-selectin on the cell membrane (Fig.  7). 
 
 
scFv 10A control scFv  
A B 
 
  
 
  
Figure 7  Immunofluorescent microscopy of antibody binding to P-selectin in 
HUVECs treated with TNFα. 
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To confirm whether scFv 10A bound to P-selectin in vitro, HUVECs 
were treated with ionizing radiation to stimulate P-selectin expression on the 
cell membrane before being incubated with antibody. Cells were stained with 
DAPI nuclear stain (blue) and scFv 10A was conjugated with Cy3 dye (red). 
During immunofluorescent microscopy of the treated cells, it was observed 
that scFv 10A antibody bound to P-selectin protein on the cell membrane of 
cells treated with a radiation dose of 3 Gy 30 minutes after treatment (Fig. 8 ). 
ScFv10A antibody did not show significant binding to cells treated with sham 
radiation of 0 Gy (Fig. 8 ). 
 
 
 
 
 
 
 
 
3 Gy radiation
A B
0 Gy radiation 
 
 
Figure 8 Immunofluorescent microscopy of antibody binding to P-selectin in 
HUVECs treated with radiation. 
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In Vivo Model Results 
 
Optical Imaging 
To determine whether scFv 10A bound to P-selectin in vivo, nude mice 
with Lewis lung carcinoma xenografts were treated with radiation before 
receiving antibody. Near-infrared (NIR) fluorescence imaging studies were 
performed in order to evaluate the tumor targeting ability of scFv 10A as 
compared to control antibody scFv 4A (Fig. 9). Specific targeting was seen 
with scFv 10A to the tumor treated with 6 Gy (left leg) as compared to 
untreated tumor (right leg) and the rest of the body as early as 4 hours post-
injection (Fig.9). Mice treated with scFv 4A did not show tumor-specific 
binding, with considerable antibody still circulating in the kidneys at 4 hrs 
post-injection.  
 
 
 scFv 10A-Cy7 scFv 4A-Cy7 
A B
 
 
 
 
 
 
 
Figure 9  NIR imaging of in vivo scFv biodistribution at 4 hrs post-injection. 
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The antibody biodistribution in the animal was tracked using near-
infrared imaging at 4 hours after injection. Fluorescence intensity of different 
regions of interest (ROI) was created by quantifying photons emitted per 
second for each desired area.  The ratios of irradiated tumor, control tumor 
and the rest of the body per kilogram of body weight are shown (Fig. 10).  The 
ratio of fluorescence intensity of the irradiated tumor to the control tumor is 
approximately 25:1, and the ratio to the rest of the body is over 100:1.   
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Figure 10  Graph of tumor to body ratios from NIR imaging 
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In order to confirm tumor binding of scFv 10A, tumors were excised and 
imaged ex vivo (Fig. 11). The irradiated tumor shows significantly more 
fluorescence intensity as compared to the unirradiated control ScFv 4A 
exhibits no tumor binding. 
 
 
Irradiated 
tumor 
Unirradiated 
tumor 
 
 
 
 
       
 
 
 
 
 
 
Figure 11  NIR imaging of ex vivo scFv 10A in tumors treated with and 
without radiation at 4 hours post-injection. 
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Nuclear Imaging 
To evaluate the P-selectin targeting ability of scFv 10A in vivo, and 
validate the results observed in the near-infrared fluorescence imaging 
studies, gamma camera imaging studies were performed using the γ ray 
emitting radionuclide 111In. In order to do this, a chelator (DTPA) was used to 
sequester the 111In and enhance stability in vivo.  The scFv 10A antibody was 
also modified to contain a cysteine residue (scFv 10Acys) in order to allow 
conjugation of the DTPA chelated 111In.  
To determine whether scFv 10Acys bound to P-selectin in vivo, nude 
mice bearing Lewis lung carcinoma tumors were treated with the tumor on the 
left side of each animal receiving a radiation dose of 6 Gy and the tumor on 
the right side receiving an intratumoral injection of TNFα as an internal 
positive control. Negative controls consisted of mice with tumors that were 
treated with no radiation (sham radiation dose of 0 Gy). Three hours following 
radiation, 111In-DTPA conjugated scFv 10Acys was injected into both groups 
of mice.  
Beginning 24 hours after injection all mice were imaged on a gamma 
camera imaging system at 24 hours post-injection and every 24 hours after 
for up to 10 days (or approximately 3 half-lives for the 111In). Specific targeting 
was seen with scFv 10Acys to the tumor treated with 6 Gy (left leg) and the 
tumor treated with TNFα as compared to untreated control tumors.  Binding 
was observed at 24 hours and continued for up to 10 days post-injection. 
Figure 12 shows a representative image of 111In-DTPA conjugated scFv 
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10Acys targeting a Lewis lung carcinoma tumor treated with 6 Gy showing 
tumor targeting for up to 10 days after injection.  
 
        
 
 
Figure 12  Gamma camera imaging of in vivo scFv biodistribution at 10 days 
post-injection. 
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Figure 13 below shows a higher percentage (>10%) of binding activity in 
tumors treated with 6 Gy radiation than tumors treated with TNFα. Binding 
activity dropped approximately 30% in radiation-treated tumors over a period 
of ten days. Binding activity in TNFα treated tumors decreased approximately 
45% over ten days. Both radiation-treated and TNFα treated tumors showed 
increased tumor binding activity over tumors treated with sham radiation of 0 
Gy. 
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Figure  13 Tumor binding activity of three different treatments with a gamma 
camera. 
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ScFv 10Acys binds tumors in vivo treated with both radiation and TNFα 
treatment for up to 10 days post-injection (Fig. 14). However, radiation 
produced greater P-selectin binding than TNFα. Tumor binding was nearly 
five times higher in radiation treated tumors as compared to untreated tumors. 
Tumor binding remained constant for up to two days before steadily 
decreasing up to ten days. As expected, percent uptake was highest in the 
liver, followed by radiation treated tumor, kidneys, bladder, TNFα treated 
tumor, and untreated tumor. Liver, kidney and bladder uptake decreased by 
approximately half over a time period of ten days.  
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Figure 14  Percent uptake of 111In-DTPA-scFv 10Acys in various organs over 
10 days after injection as measured with a gamma camera. 
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Discussion 
Expression of P-selectin in tumor vascular endothelium after exposure 
to ionizing radiation enables the preferential delivery of labeled anti-P-selectin 
scFv antibodies to irradiated tumors. Previous studies with radiolabeled scFv 
demonstrated the site-specific localization of the antibodies in the targeted 
tumor vascular cells. In our study, we described the selective targeting of 
scFv antibodies to tumors in vivo using two methods: NIR fluorescence 
imaging and gamma camera imaging. Near-infrared (NIR) imaging is a useful 
non-invasive tool for visualizing tumor targeting in vivo, and a powerful 
complement to nuclear imaging techniques. NIR imaging has the advantages 
of using neither ionizing radiation nor radioactive materials, and is becoming a 
more important tool for imaging of animals in preclinical models. Fluorescent 
probes, such as Cy7, allow the visualization of anatomical, functional and 
molecular events in small animals. These attributes make it ideal for studying 
the molecular target P-selectin and its role in tumor vasculature. With better 
understanding of tumor angiogenesis, it is possible to develop P-selectin 
targeted therapies. To achieve this, imaging studies with both NIR and 
nuclear techniques were performed and tumor targeting to P-selectin was 
studied. NIR fluorescence imaging was performed using a Cy7-conjugated 
scFv antibody, and gamma camera imaging was performed using an 111In-
DTPA-conjugated scFv antibody modified to include a cysteine residue for 
conjugation purposes. Combining both optical imaging and nuclear imaging 
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techniques enabled the confirmation of results using complementary imaging 
modalities. 
Optical imaging techniques such as NIR fluorescence imaging take 
advantage of recent developments in fluorescent probes in the near-infrared 
region of the spectrum. Conjugation of Cy7, a fluorescent probe with 
excitation at 680 nm and emission at 775 nm, did not have significant effect 
on the optical properties of Cy7 dye and did not affect the receptor binding 
affinity or specificity of the scFv antibodies to P-selectin. Since NIR 
fluorescence intensity is a function of optical path length between excitation 
light and the subject, subcutaneous tumor models were chosen for this study. 
Imaging was done both in vivo and ex vivo with excised tumors in order to 
validate signal detected in in vivo images. As expected, fluorescence intensity 
was lesser in vivo as compared to direct imaging of dissected tissues. Other 
researchers have noted similar observations when imaging with and without 
skin and detected an attenuation of fluorescence intensity by approximately 
44% 32. This is most likely caused by the loss of excitation and emission light 
by penetration of the skin, in addition to scattering caused by the skin. 
Because of these issues, gamma camera imaging was used to minimize the 
effects of skin scattering on imaging of tumor binding. 
The binding of labeled scFv antibody to P-selectin was tested using in 
vitro and in vivo techniques. Human umbilical vein endothelial cells (HUVECs) 
treated with TNFα, a potent stimulator of P-selectin, were incubated in the 
presence of scFv antibody and immunostained showing binding to P-selectin 
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present on cells. Cell staining was observed all over the cell membrane, 
consistent with the observed location of P-selectin after TNFα and radiation 
treatment 7. Staining of cell membranes was not present when scFv not 
specific to P-selectin (control scFv) was used. Immunofluorescence confirms 
that scFv 10A antibody selectively binds to HUVEC cells expressing P-
selectin and does not bind to other cells. Therefore, we have successfully 
demonstrated that scFv 10A antibody is specific to human P-selectin 
expressed on the surface of vascular endothelium. 
In vivo NIR fluorescence imaging of mice with irradiated and 
unirradiated tumors given Cy7-labeled scFv 10A and 4A showed significant 
targeting of irradiated tumors using scFv 10A as early as 4 hours post 
treatment. Binding in tumors was measured to be over 25 times higher than in 
unirradiated tumors and over 100 times higher than the rest of the body. 
Direct imaging of excised tumors confirmed these results with significant 
binding in irradiated tumors as compared to unirradiated tumors.  Tumor 
binding was not observed in animals treated with scFv 4A. 
In order to further study the kinetics of this scFv antibody, the antibody 
was modified to include a cysteine residue for conjugation to DTPA and was 
then radiolabeled with 111In, a gamma emitter. This modified antibody 
construct was used to image mice with irradiated tumors, TNFα treated 
tumors and unirradiated tumors. The ionizing gamma rays emitted from the 
111In penetrated through the tumor and surrounding layers of skin, providing 
greater sensitivity with gamma camera imaging as compared to NIR 
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fluorescence imaging. In vivo imaging showed significant accumulation of 
radiolabelled scFv 10Acys in irradiated tumor tissue as compared to TNFα 
treated tumors, unirradiated tumors and the rest of the body for up to 10 days 
post-injection. Our data show that scFv 10Acys selectively targets P-selectin 
in vivo as induced with both radiation and TNFα treatment at 10 days post-
injection. However, radiation produced greater P-selectin binding than TNFα. 
Tumor binding was nearly five times higher in radiation treated tumors as 
compared to untreated tumors, again suggesting antibody binding to be 
higher in P-selectin expressing tumors. Biodistribution of the scFv 10Acys 
antibody showed higher uptake in the liver, kidneys and bladder as compared 
to tumors treated with radiation, TNFα, and no treatment. Percent uptake was 
highest in the liver due to processing by macrophages, followed by radiation 
treated tumor, kidneys, bladder, TNFα treated tumor, and untreated tumor.  
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Future Work 
 Imaging P-selectin targeting in vivo provides a stepping stone to 
achieving radiation-guided drug delivery to P-selectin expressing tumors in 
vivo.  Follow up work in this area would include the investigation of 
therapeutic radionuclides and compatible chelators that could be linked to the 
identified antibody scFv 10A.  Effects on tumor growth must be studied over 
time to determine if this approach produces therapeutic effects. In addition, 
safety and toxicity studies must be done to determine the effects of these 
radionuclides on vital organs over time.  Targeted drug delivery to P-selectin 
in irradiated tumors should be studied using chemotherapeutic and 
radiosensitizing drugs commonly used in radiation therapy.  Combining tumor 
imaging with targeted drug delivery would enable important parameters such 
as biodistribution, pharmacokinetics and bioavailability to be studied in more 
detail. By using the targeting capability of antibodies, and exploiting the side-
effects of radiation therapy, it is possible to target and treat tumors locally with 
both radiation and chemotherapeutic drugs much more effectively. 
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CHAPTER IV 
 
CONCLUSIONS 
 
In this study we have demonstrated the successful non-invasive in vivo 
targeting of an antibody to radiation-inducible neoantigen P-selectin, in a 
heterotopic Lewis lung carcinoma model by using near-infrared fluorescence 
imaging and gamma camera imaging. In our preliminary optical imaging 
study, it was observed that tumor-specific binding was seen as early as 4 
hours post-injection. Binding in irradiated tumors was over 25 times higher 
than in unirradiated tumors and over 100 times higher than the rest of the 
body.  It was also shown that scFv 10A binds P-selectin in TNFα and 
radiation treated HUVECs in vitro. Gamma camera imaging showed that the 
modified scFv 10A also showed successful targeting to P-selectin with tumor 
binding lasting for up to 10 days post-injection.  Therefore, radiation-guided 
targeting of P-selectin for the tumor-specific delivery of therapeutic drugs and 
radionuclides in vivo is a feasible approach. 
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